NCT06365359
Systemic Lupus Erythematosus and Chlordecone Impregnation in Martinique
Recruiting · Not specified · University Hospital Center of Martinique · registry updated 2025-03-31
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Chlordecone, an organochlorine pesticide, was widely used on banana farms in the French West Indies. Studies by Inserm and health authorities have confirmed the contamination of the food chain and the majority of the population of the French West Indies by chlordecone. Epidemiological studies conducted in the French West Indies have shown that exposure to chlordecone at the levels observed is associated with an increased risk of developing several diseases, including premature birth and prostate cancer. Many of the adverse effects associated with chlordecone could be explained by its estrogenic hormonal properties, and systemic lupus erythematosus (SLE) is an autoimmune disease whose sensitivity to estrogen is well known and is reflected by 1) its clear predominance in women, 2) its predominance in women of childbearing age, 3) its risk of exacerbation in the event of pregnancy. Chlordecone has the potential to modify the activity of SLE through mechanisms other than its pro-estrogenic effects. In rats, chlordecone was observed to induce alterations such as a reduction in lymphocyte count, thymic atrophy, and a decrease in splenic germinal centers and NK cells....
Inclusion
- Patients with systemic lupus erythematosus according to the ACR 1997 or ACR/EULAR 2019 criteria,
- Present in the active line of the internal medicine department of the Martinique University Hospital since 2005,
- Whose illness has been progressing for at least 3 years,
- Living in Martinique or Guadeloupe for at least 1 year,
- Patients who have given their free, informed and written consent.
Exclusion
- Patients for whom kidney disease cannot be authenticated or ruled out (refusal, contraindication or impossibility of renal biopsy),
- Patients without social security coverage,
- Current legal protection,
- Patients who have not given their consent to the use of their data,
- Pregnant or breastfeeding women.